AbCellera Appoints Biotech Veteran Dr. Lynn Seely to Board of Directors
ABCL•AbCellera has appointed Dr. Lynn Seely to its board of directors, effective July 2026, expanding its governance team with her biotech leadership. Dr. Seely brings over two decades of drug development and strategic planning experience from senior executive and investment roles.
1. Board Appointment Details
On July 6, 2026, AbCellera appointed Dr. Lynn Seely to its board of directors, adding a seasoned biotech executive to its governance structure.
2. Dr. Seely’s Professional Background
Dr. Seely has over 20 years of experience in drug development and strategic finance, having served in senior leadership and investment roles across the life sciences industry.
3. Strategic Governance Impact
Her expertise in pipeline advancement and capital strategy is expected to strengthen board committees and support AbCellera’s expansion of its antibody discovery platforms.
